489 related articles for article (PubMed ID: 22236804)
21. Correlation between airflow limitation and airway dimensions assessed by multidetector CT in asthma.
Hoshino M; Matsuoka S; Handa H; Miyazawa T; Yagihashi K
Respir Med; 2010 Jun; 104(6):794-800. PubMed ID: 20053544
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
Menzella F; Facciolongo N; Piro R; Formisano D; Roggeri A; Simonazzi A; Castagnetti C; Carbonelli C; Zucchi L
Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
[TBL] [Abstract][Full Text] [Related]
23. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J
Respiration; 2013; 86(4):280-7. PubMed ID: 23880883
[TBL] [Abstract][Full Text] [Related]
24. [Airway inflammation and peripheral airway function in asthmatic patients with different control levels].
Pan Y; Huang KW; Ye Q; Liu XS; Wu BM; Zhang J; Chang XH; Lu Y; Wang C
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep; 32(9):679-84. PubMed ID: 20079282
[TBL] [Abstract][Full Text] [Related]
25. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
[TBL] [Abstract][Full Text] [Related]
26. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
27. Airway wall thickness of allergic asthma caused by weed pollen or house dust mite assessed by computed tomography.
Liu L; Li G; Sun Y; Li J; Tang N; Dong L
Respir Med; 2015 Mar; 109(3):339-46. PubMed ID: 25524508
[TBL] [Abstract][Full Text] [Related]
28. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.
de Llano LP; Vennera Mdel C; Álvarez FJ; Medina JF; Borderías L; Pellicer C; González H; Gullón JA; Martínez-Moragón E; Sabadell C; Zamarro S; Picado C;
J Asthma; 2013 Apr; 50(3):296-301. PubMed ID: 23350994
[TBL] [Abstract][Full Text] [Related]
29. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
[TBL] [Abstract][Full Text] [Related]
30. Airway wall thickening in patients with cough variant asthma and nonasthmatic chronic cough.
Matsumoto H; Niimi A; Tabuena RP; Takemura M; Ueda T; Yamaguchi M; Matsuoka H; Jinnai M; Chin K; Mishima M
Chest; 2007 Apr; 131(4):1042-9. PubMed ID: 17426208
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
32. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of CT small airway measurement with clinical and inflammation factors in asthma patients].
Li MJ; Chang C; Wang XH; Wang J; Liang Y; Zhu Q
Zhonghua Yi Xue Za Zhi; 2018 Jul; 98(27):2184-2188. PubMed ID: 30032523
[No Abstract] [Full Text] [Related]
34. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
35. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
37. [Relation between clinical severity of bronchial asthma and degree of airway inflammation assessed by the eosinophilic leukocyte count in induced sputum].
Chlumský J; Pokorná H
Vnitr Lek; 2001 Sep; 47(9):604-8. PubMed ID: 11715664
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
[TBL] [Abstract][Full Text] [Related]
39. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
Adv Med Sci; 2011; 56(2):318-22. PubMed ID: 21940268
[TBL] [Abstract][Full Text] [Related]
40. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
